Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vivus Muse

Executive Summary

Use of the term "urethral suppository" in a consumer print ad for the transurethral alprostadil erectile dysfunction therapy represents an "unfamiliar medical term," FDA maintains in April 1 letter to firm. "The majority of men exposed to this advertisement will not understand that Muse is a suppository designed to be inserted in the opening of a man's penis," FDA explains. Muse TV broadcast ads were the subject of a February NOV letter from FDA for inadequate information on side effects, including hypotension ("The Pink Sheet" March 9, p. 12)

You may also be interested in...

Vivus Muse Ad Omits Route Of Administration, FDA Warning Letter Says

A television advertisement for Vivus' erectile dysfunction urethral suppository Muse (alprostadil) fails to disclose the route of administration, an FDA warning letter says

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts